What Негрустин treats: Main Uses and Benefits

Based on the established therapeutic ontology, Негрустин is applied across domains where additional symptomatic support is needed to address emotional disturbances and mild mood alterations. Its primary relevance is within the management of mild to moderate depressive states and associated emotional challenges.

The medication is commonly used to help with the core symptomatic manifestations of low mood, persistent sadness, and a reduction in emotional well-being. It is relevant for managing co-occurring symptoms of anxiety, nervous tension, and marked irritability that often create noticeable physiological strain, as well as psychovegetative complaints like sleep problems and lack of energy. It is applied in situations involving certain distressing symptoms, where supportive relief is appropriate.

This phytotherapeutic extract is generally considered relevant for conditions characterized by periods of heightened symptoms and may be part of symptomatic management when manifestations interfere with daily functioning. It provides support that generally contributes to easing the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Support for Symptoms of Anxiety and Mild Depression

---

Regulatory References

1. NIH NCCIH overview

Official Eligibility Rules for Негрустин

The eligibility for Негрустин (St. John's Wort Herb Dry Extract) is strictly governed by regulatory documentation, which defines specific populations for whom use is permitted, restricted, or contraindicated.

Category	Official Regulatory Classification
Populations Allowed	Adults and Older People (Aged 18 and over) for the labeled use.
Populations Contraindicated	Patients with Hypersensitivity to St. John's Wort or any excipients.
	Patients concurrently taking critical medicines (e.g., immunosuppressants, anticoagulants, certain antivirals, hormonal contraceptives).
	Patients undergoing phototherapy or photodiagnostic procedures.
Age-Related Rules	Not recommended for use in children and adolescents under 18 years due to insufficient data on safety and efficacy.
Reproductive Status	Not recommended for use during pregnancy or lactation (breastfeeding).

Eligibility-Related Restrictions: Use requires caution in fair-skinned individuals, who must avoid excessive sun exposure, solariums, or sunbeds due to the potential for photosensitivity reactions.

Interactions with other medicines and products

Негрустин (St. John's Wort extract) has a high potential for clinically significant interactions, primarily driven by its ability to induce certain drug-metabolizing enzymes and transport proteins. This induction process, mainly mediated by the constituent hyperforin, leads to an accelerated breakdown of co-administered medicines, resulting in reduced plasma concentrations and a potential loss of their therapeutic effect.

Key interacting medicines and product categories are listed below. Concomitant use with these agents is classified as a major interaction risk.

Mechanism	Interaction Classification	Affected Medicinal Product Categories
Pharmacokinetic Induction (CYP/P-gp)	Contraindicated	Immunosuppressants (e.g., Ciclosporin), Anticoagulants (e.g., Warfarin), HIV Antivirals (Protease and NNRTI Inhibitors), Digoxin, Oral Contraceptives
Pharmacodynamic	High Risk	Antidepressants (e.g., SSRIs), Triptans (migraine medicines)

Combinations with immunosuppressants, such as ciclosporin, can lead to graft rejection in transplant patients. Its use with warfarin can decrease the anticoagulant effect, raising the risk of blood clots. Furthermore, co-administration with serotonergic agents like SSRIs can increase the risk of adverse reactions consistent with Serotonin Syndrome. When St. John's Wort is discontinued, the blood levels of interacting medicines may rapidly increase, posing a risk of toxicity, which requires careful monitoring.

The action of the St. John's Wort extract is defined by a mechanism of action across multiple neurotransmitter systems in the central nervous system (CNS).

Unique Non-Competitive Monoamine Enhancement

This domain focuses on the primary molecular action: the constituent Hyperforin indirectly blocks the reabsorption (reuptake) of chemical messengers, including Serotonin, Norepinephrine, and Dopamine, into the presynaptic nerve cell. This blockage is mediated by a subtle alteration of the neuronal ion balance ( Na^+ ions) rather than direct binding to the transporter proteins (SERT, NET, DAT). This interaction results in an elevated concentration of these monoamines within the synaptic cleft.

Adaptive Receptor Regulation and System Modulation

• The elevated availability of neurotransmitters triggers the adaptive regulation of receiving structures (receptors) on the postsynaptic neuron, involving long-term changes in beta-adrenergic and 5- HT2 receptor sensitivity.
• This time-dependent response solidifies the chemical change into a sustained physiological change within the affected neural circuits, promoting a more regulated state associated with affective signaling and HPA axis activity.
• The overall physiological action is achieved through the synergistic combination of the extract's components, which results in simultaneous modulation across several regulatory pathways, collectively defining the extract's full mechanistic breadth.

Administration and Dosing Principles

Негрустин (St. John's Wort dry extract) is officially administered via the oral route, typically supplied in solid dosage forms such as capsules or film-coated tablets. These forms are intended to be swallowed whole with water, ensuring proper administration of the full dose.

Standard adult dosing regimens vary significantly based on the extract concentration and regulatory classification (Traditional versus Well-Established Use). For milder indications, certain preparations are administered as one capsule daily. However, for well-established uses, the total daily dose often falls within the range of 600 mg to 1800 mg of the extract, which may be taken as a single dose or divided into two or three administrations per day. The preparation is designated for oral short-term use only.

Procedural and Time Constraints

The usage protocol establishes explicit constraints on the treatment course. If the desired support is not observed, the official instruction is that patients should consult a healthcare professional if symptoms persist or worsen after approximately four weeks of use. This duration defines the initial observation phase of the therapeutic course.

Regarding the schedule, if a dose is missed, patients are instructed to continue with their next scheduled dose at the usual time and are explicitly advised not to take a double dose to compensate. Additionally, the official labeling does not recommend the use of the extract in children and adolescents under the age of 18 years due to insufficient safety data.

Research evidence / Overview of studies for Негрустин

The research base for the active component in Негрустин, St. John's Wort Herb Dry Extract (Hypericum perforatum L.), primarily consists of clinical trials and comprehensive analyses of those trials conducted worldwide. These studies provided data used in research exploring how symptoms change over time, contributing to the broader understanding of symptom patterns observed so far.

---

Evidence for Use in Mild to Moderate Depressive Episodes

The extract was studied for its application in mild to moderate depressive episodes and associated mood alterations. Researchers primarily conducted Randomized Controlled Trials (RCTs) to assess this use. These short-term studies were evaluated in adult outpatients who presented with symptoms where intensity may vary. The main purpose was to monitor outcomes related to systemic imbalance by measuring changes in depressive symptom severity using standardized scales like the Hamilton Rating Scale for Depression (HAM-D).

Syntheses of these trials, including systematic reviews and large meta-analyses, reported data showing patterns observed in the studied populations. Research has explored the findings compared to an inactive substance (placebo), and against certain active standard pharmaceutical comparators when used for mild-to-moderate depression. This evidence contributes to understanding symptom patterns, but findings were mixed in some instances due to notable heterogeneity (variability) in the extract dosage and standardization used across different trials.

Comparing the Extract to Placebo and Active Treatments

The clinical research involved comparisons where the extract was studied for short-term symptom changes in relation to both a placebo and, separately, to some established treatments. Studies were designed to compare the extract against an inactive placebo and against existing standard pharmaceutical antidepressants to understand the relative performance reported in the clinical literature. Research explored short-term symptom changes, which included comparisons to placebo to examine measured outcomes.

---

Long-Term Studies and Duration of Effect

Most available research exploring short-term symptom changes has been confined to short-term observation. The typical follow-up duration in the main trials was observed in defined time intervals, most often ranging from 4 to 12 weeks. Data are still emerging, and the studies offer limited insight into the duration of any change beyond the immediate short-term window, meaning the long-term effects are not fully established.

---

What is Still Uncertain About the Extract

The body of evidence is largely based on studies of generally healthy adult outpatients presenting with mild-to-moderate severity. The results apply only to the populations studied in the RCTs, and the studies consistently excluded patients with severe depression or complex psychiatric conditions. Few research data are available for several key groups, such as children, adolescents, and pregnant women. Comparative evidence remains limited for certain specific populations, and there is a need for more comprehensive research into the extract's use in patients with other concurrent medical conditions. Research clarifies what is known—and what is still uncertain—about the extract.

Key Studies & References National Center for Complementary and Integrative Health (NCCIH): St. John's Wort

Common questions about Негрустин (FAQ)

Q: What is the main ingredient in Негрустин?

The primary active component in this medicine is the dry extract derived from the plant Hypericum perforatum L. This plant is commonly known as St. John's Wort. Official product documents identify this extract as the substance responsible for the therapeutic action.

Q: Is Негрустин an antidepressant?

Official documents classify this product as a well-established or traditional herbal medicine. Its recognized use is for the relief of symptoms related to mild-to-moderate depressive episodes and temporary mental exhaustion. The mechanism of action is described as influencing several neurotransmitter systems in the brain.

Q: What is Негрустин used for, generally?

According to official documents, the medicine is used for the symptomatic treatment of mild-to-moderate depressive episodes. It is also indicated for the relief of symptoms of temporary mental exhaustion.

Q: Does taking Негрустин affect other lab test results?

The official information describes that this extract can cause the induction (speeding up) of certain enzymes and transport proteins (like CYP450). This process alters how the body breaks down many other drug substances, which is why care is required with co-administered medicines.

Q: What is the source of the active compound in Негрустин?

The active substance is derived from the above-ground flowering parts of the plant Hypericum perforatum L. This refers to the parts of the St. John's Wort plant that are used to make the dry extract.

Q: Why is St. John's Wort often mentioned with Негрустин?

Негрустин is a commercial name for a medication that contains the dry extract of the plant Hypericum perforatum. St. John's Wort is the common name for this plant, explaining the frequent association between the two names.

Q: What are the most commonly reported side effects of Негрустин?

Official documents list the commonly reported undesirable effects. These include gastrointestinal discomfort or disorders, allergic skin reactions, feelings of fatigue, and restlessness.

Q: Can Негрустин cause changes to my skin?

Yes, undesirable effects listed in official product information include allergic skin reactions. Additionally, warnings exist that fair-skinned individuals may react with intensified sunburn-like symptoms if they are exposed to intense sunlight or UV radiation while using the medicine.

Q: Is it normal to feel a change in sleep patterns when starting Негрустин?

Changes in alertness or rest are possible, as official undesirable effects include both fatigue and restlessness. Any significant or persistent changes observed should be discussed with a healthcare professional.

Q: Can Негрустин be taken while using oral contraceptives?

Official warnings note that this extract can reduce the plasma concentrations of hormonal contraceptives. This potential reduction may lead to decreased birth control reliability, and the product information indicates that additional contraceptive measures are advised.

Q: Does Негрустин interact with blood thinning medications?

Yes, official contraindications and interaction warnings specifically list certain blood thinning agents, such as warfarin, as agents that pose a major risk. Concomitant use with these types of medications is listed as contraindicated or requires special caution.

Q: Who should not use Негрустин, according to official warnings?

Contraindications listed in the official documents include hypersensitivity to the active substance itself. Also, the use is contraindicated when taken alongside specific medicines, including cyclosporine, tacrolimus, certain protease inhibitors, irinotecan, and warfarin. The complete list of medicines to avoid is provided in the official product information.

Q: Is Негрустин allowed during pregnancy?

The use of the extract during pregnancy is not recommended. This advisory is based on a stated lack of sufficient clinical data regarding its effects during this period.

Q: What are the concerns about using Негрустин while breastfeeding?

The use of the extract while breastfeeding is not recommended. This stance is based on the absence of sufficient data regarding the safety of the medicine during the lactation period.

Q: Do studies support the use of Негрустин for mild mood changes?

The product is officially indicated for the relief of symptoms in mild-to-moderate depressive episodes. Its regulatory status as a 'Well-Established Use' or 'Traditional Use' herbal product confirms its recognized application for these conditions.

Q: What type of research evidence is available for Негрустин?

The product is regulated by the European Medicines Agency (EMA) and is classified as either a Well-Established Use or Traditional Use herbal medicine. This regulatory status indicates that its use is supported either by established clinical studies or by long-standing documented usage.

Q: Have there been large-scale clinical trials on Негрустин?

The regulatory status as a 'Well-Established Use' herbal medicinal product is based on established clinical studies and data on its efficacy and safety. This designation means the information has been reviewed and validated by regulatory authorities.

Q: Is Негрустин studied for generalized feelings of stress?

Official indications include the relief of temporary mental exhaustion. This condition is often associated with feelings of strain or stress.

Q: What should I do if I experience a severe side effect from Негрустин?

Official product information indicates that if any undesirable effects, or symptoms not mentioned in the documentation, occur, consultation with a doctor or a pharmacist is appropriate.

Q: Can Негрустин affect my ability to drive or operate machinery?

Official documents explicitly state that no adequate studies on the effect on the ability to drive and use machines have been performed. Due to potential effects like fatigue or restlessness, the product label mentions that the effect on driving ability is not fully studied.

Q: What is the official recommended purpose of Негрустин?

The official purposes are the symptomatic treatment of mild-to-moderate depressive episodes and the relief of temporary mental exhaustion. These are the regulatory-defined conditions for which the product is authorized.

Q: Is Негрустин approved by major international health organizations?

The product is regulated in Europe under the European Medicines Agency (EMA) through its herbal monographs. This indicates its formal recognition and regulation by a major intergovernmental body.

Q: Is there a risk of interaction with herbal supplements when taking Негрустин?

The extract interacts with other substances by altering how the body metabolizes them. Because of the potential for interactions with any substance, official documents indicate that patients using other medicines, including herbal supplements, should discuss this with a healthcare professional.

Q: Can Негрустин affect sun sensitivity?

Official warnings state that intense UV-exposure, such as sunbathing or sunlamp use, should be avoided during treatment. This is because the extract may increase the skin's sensitivity to light (photosensitivity).

Q: What are the known contraindications listed in the official documents for Негрустин?

Contraindications include hypersensitivity to the active substance and concomitant use with specific medicines like cyclosporine, tacrolimus, certain protease inhibitors, irinotecan, and warfarin. The complete list of medicines to avoid is provided in the official product information.

Q: Are there any official reports of serious reactions to Негрустин?

Official documents describe the risk of serotonergic effects, such as agitation, confusion, or tremor, when the extract is combined with certain antidepressants. These effects can be serious. Cases of seizures and confusion have also been reported after massive overdose.

Q: What is the expected timeline for relief of symptoms with Негрустин?

The regulatory documents suggest that the onset of the desired effect is generally expected within approximately four weeks of starting treatment. If symptoms persist beyond this time, the official protocol suggests discussing the status with a healthcare professional.

Q: How does Негрустин interact with medications for migraine?

The extract may contribute to serotonergic effects when combined with triptans, which are a class of medications used to treat migraines. The interaction risk means that patients using these medicines should discuss their combination with a healthcare professional.

Q: Is the drug considered safe for long-term use?

Official information describes the product for oral short-term use only. The regulatory documents state that treatment should not be taken for a period longer than six months without first consulting a healthcare professional.

Q: What are the possible signs of an allergic reaction to Негрустин?

Undesirable effects listed in the product information include allergic skin reactions. Any adverse reactions or suspected allergic reactions observed should be discussed with a doctor or pharmacist.

Q: Are there official warnings about combining Негрустин with other psychiatric medications?

Yes, official warnings exist regarding the combination with certain psychiatric medicines. The extract may contribute to serotonergic effects when used alongside antidepressants, such as serotonin reuptake inhibitors or buspirone, and discussion with a healthcare professional is indicated.

Official Storage and Disposal Instructions

Regulatory documentation defines strict environmental conditions necessary to maintain the stability of Negrustin (St. John's Wort Dry Extract) throughout its labeled shelf-life.

Storage Conditions

Requirement	Description
Temperature	Store at a temperature not exceeding 25°C (77°F).
Protection	Keep the product in the original container, tightly closed, to protect from light and moisture.
Safety	Must be stored out of the sight and reach of children.

Disposal Requirements

Any unused or expired Negrustin product must not be disposed of via household trash or wastewater. Disposal must be carried out according to local regulations for pharmaceutical waste, which generally involves returning the product to a pharmacist or designated collection point.